News & Press
Drug Development & Delivery, April 2017
Cancer remains the second leading cause of death and represents the largest category of new medicines. A range of new mechanisms is expected to drive innovation and growth for the CDMOs that have the right expertise and capabilities in this area, says Jason Bertola, Director, Global Highly Potent & Oncology Platform, CordenPharma International. “Greater understanding of cancer progression has led to the development of increasingly targeted approaches, which mean not only increased safety and efficacy for the patients but also increased manufacturing requirements and need for containment and engineering controls,” he says. “For example, antibody drug conjugates (ADCs) offer better safety profiles for patients, but manufacturers must be able to produce and handle cytotoxic drugs that are significantly more potent than their chemotherapeutic predecessors.”
Despite significant focus on biologics, small molecules still represent more than half of the total market. For instance, tyrosine kinase inhibitors and poly ADP-ribose polymerase inhibitors are among the small-molecule targeted therapies. These products are also driving the need for oral solid dose highly potent manufacturing. Some estimates predict oral oncolytics to be 25%-30%2 of the market, double the figures from 10 years ago.
CordenPharma’s service offering targets the oral formulation development and manufacturing of oncolytics. “Recent investments have expanded our capabilities to develop and supply clinical trial materials and small-scale manufacturing. Engineering controls are in place to allow the safe handling of compounds in development and manufacturing,” he says.